Skip to main content

Table 2a Clinical characteristics at randomisation used in the minimisation algorithm

From: Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited

   No. (%)
Region1 NW Europe (UK, Austria, Belgium, Switzerland) 1589 (52%)
  Scandinavia (Norway, Sweden) 501 (17%)
  Australasia 179 (6%)
  Southern Europe (Italy, Portugal) 408 (13%)
  Eastern Europe (Poland) 347 (11%)
  Americas (Canada, Mexico) 11 (0%)
Sex Female 1570 (52%)
  Male 1465 (48%)
Age < = 70 years 697 (23%)
  > 70 years 2338 (77%)
Age (more detail) 18-50 127 (4%)
  51-60 203 (7%)
  61-70 367 (12%)
  71-80 721 (24%)
  81-90 1407 (46%)
  over 90 210 (7%)
NIHSS2 0 to 5 612 (20%)
  6 to 10 852 (28%)
  11 to 15 601 (20%)
  16 to 20 542 (18%)
  21 to 35 428 (14%)
Stroke syndrome Other 2703 (89%)
  Lacunar 332 (11%)
Delay in randomisation 0-3 hours 849 (28%)
  > 3 hours 2186 (72%)
Delay (more detail) 0-3 hours 849 (28%)
  3-4.5 hours 1178 (39%)
  4.5-6 hours 1007 (33%)
  > 6 hours3 1 (0%)
Antiplatelet agents < = 48 hours before randomisation Yes 1565 (52%)
  No 1470 (48%)
  1. 1. From January 2006, the randomisation procedure has been stratified by world region and minimises on prognostic factors within world region, using a random element.
  2. 2. For 244 patients in initial phase of the trial, NIHSS was not measured directly, but it was subsequently approximated using an algorithm (derived from subsequent patients in the trial based on clinical characteristics that were measured at baseline).
  3. 3. Protocol violation